2 min read
Most regulatory teams entering Brazil arrive with a working assumption: if the API is approved — FDA, EMA, ICH-aligned dossier, GMP certificate in hand — the Brazil submission is largely a formatting exercise. It is not. The ANVISA API pathway has its own architecture, its own sequencing logic, and its own system infrastructure. None of it maps cleanly onto what the FDA or the EMA taught you. And the gap between what you expect and what ANVISA requires is exactly where timelines break down.
The DIFA is not your DMF
In an FDA context, the Drug Master File is a support document. It travels with the NDA, it informs the review, but it does not have an independent approval lifecycle of its own. ANVISA works differently. The DIFA — Active Pharmaceutical Ingredient Dossier — is a standalone petition submitted directly to the agency by the DIFA holder. ANVISA evaluates it independently and, if approved, issues a CADIFA: a Letter of Suitability that confirms the API meets Brazilian regulatory standards. That CADIFA request has to exist before you can move your marketing authorization forward.What does not have to exist is the CADIFA itself: ANVISA requires the DIFA reference number — or an issued CADIFA — as part of the drug application, and both assessments may proceed in parallel. Teams that treat the DIFA as background documentation and push toward the MA submission simultaneously discover the sequencing problem only after it has already cost them months.
GMP timing is not what you expect, either
A valid API GMP certificate is required for the marketing authorization, but it is not a prerequisite for obtaining the CADIFA itself. What matters is the order of filings, not the order of approvals. The sequence is fixed: the CADIFA request goes first — no prerequisites. The API GMP request goes second — and it requires the CADIFA request to already be on record. The MA request goes third — and it requires both the CADIFA and GMP requests to be filed. Approvals can still be pending at each stage; what cannot happen is filing out of order.
Manufacturers who treat GMP certification and CADIFA as one unified process tend to either over-sequence — waiting for GMP before touching the DIFA — or under-coordinate, letting the two tracks drift out of sync. Either way, the MA submission gets delayed at a stage that had nothing to do with the quality of the underlying science.
Solicita is not optional, and it is not automatic
, All DIFA submissions and CADIFA-related petitions run exclusively through Solicita — ANVISA's regulatory information system. For manufacturers with a Brazilian legal entity, access is straightforward. For foreign manufacturers without a CNPJ — without a registered company in Brazil — the registration into Solicita requires submitting a form to a designated ANVISA email address and waiting for credentials to be issued. There is no defined turnaround time — the process can exceed one month. And without that registration, no submission clock starts at all.
The March 2026 update to ANVISA's CADIFA issuance model — migration to a new internal system with automated information processing — does not change any of this for the applicant. What it signals, however, is consistent with the broader trajectory: ANVISA is investing in digital infrastructure to accelerate its internal workflows. The operational burden of sequencing correctly falls on the manufacturer's side, not the agency's.
Brazil does not penalize the complexity of your API. It penalizes the wrong sequence. The manufacturers who move fastest through ANVISA are not the ones with the simplest molecules — they are the ones who mapped the process correctly before they started. If you are evaluating your API registration pathway for ANVISA, speak with our regulatory team to identify where your sequence may need adjustment.
